The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis*
Lanctôt, Krista L., Masoud, Shababa T., Paes, Bosco A., Tarride, Jean-Eric, Chiu, Aaron, Hui, Charles, Francis, Philip L., Oh, Paul I.Volume:
24
Language:
english
Journal:
Current Medical Research and Opinion
DOI:
10.1185/03007990802484234
Date:
November, 2008
File:
PDF, 497 KB
english, 2008